A detailed history of Rubric Capital Management LP transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Rubric Capital Management LP holds 5,026,931 shares of TRVI stock, worth $14.3 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
5,026,931
Previous 5,026,931 -0.0%
Holding current value
$14.3 Million
Previous $15 Million 12.08%
% of portfolio
0.47%
Previous 0.44%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.44 - $3.36 $1.31 Million - $1.8 Million
-537,192 Reduced 9.65%
5,026,931 $15 Million
Q1 2024

May 10, 2024

SELL
$1.3 - $3.7 $156,386 - $445,098
-120,297 Reduced 2.12%
5,564,123 $19.2 Million
Q3 2022

Nov 14, 2022

BUY
$1.54 - $4.28 $6.02 Million - $16.7 Million
3,906,000 Added 219.63%
5,684,420 $8.75 Million
Q2 2022

Aug 15, 2022

BUY
$1.8 - $3.39 $3.2 Million - $6.03 Million
1,778,420 New
1,778,420 $5 Million

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $166M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.